Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Worth reading the earlier posts in this thread before acting on mine.
Counterpoint on Semaglutide formulation, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
I would be glad to be shown a cleaner way of putting this.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
The confident version of this sentence would be wrong, so here is the hedged one.
Building on post #35 rather than restating it.
On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
That is what the documentation says. What happens in practice is usually close.
Post #39 is right about the mechanism and I think understates the practical bit.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Marking that as an opinion rather than a finding.
Post #40 is the version of this I will quote in future. One addition.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
Worth one more sentence than it usually gets.
Post #43 describes the usual case. This is about the unusual one.
A methods point on Semaglutide formulation rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Genuine question rather than a rhetorical one: has anyone here actually observed Semaglutide formulation, as opposed to read about it? The thread is long and I cannot tell.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
A modest claim, modestly supported.
Adding the measurement that post #44 says would settle it.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Post #46 describes the usual case. This is about the unusual one.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
Worth separating two things that post #50 runs together.
Practical note on Semaglutide formulation: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Thank you for the correction. I would rather find out here than later.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
I changed my mind about Semaglutide formulation after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
Collapsed as off-topic by two members at trust level 3 or above
On post #53 — agreed on the reasoning, with one qualification.
Speaking only to Semaglutide formulation as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do not contain the same quantity of the molecule you are interested in.
Thank you — that answers what I came here to find out.
Confirming post #58 from a second method, which matters more than confirming it from a second person.
Worth separating Semaglutide formulation as a question about the compound from Semaglutide formulation as a question about the documentation. They get answered by different people and only one of them is answerable here.